While the concept of informed consent it a good one, there is a fundamental problem with the informed consent and how it is practiced today, writes Harlan Krumholz, MD, SM, professor of cardiology, epidemiology, and public health.
Two lawsuits have been filed against Anthem Blue Cross for denying coverage to 2 women for the hepatitis C medication Harvoni.
An international study has estimated that in 2013, there were 14.9 million newly diagnosed cases of cancer and 8.2 million deaths around the world.
A new payment model through the Affordable Care Act seeks to decrease cardiovascular disease for tens of thousands of Medicare beneficiaries by assessing patient risks for heart attack and stroke and then helping them to reduce those risks.


Improved survivorship rates among cancer patients has brought a growing awareness of a serious latent impact of chemotherapy and radiation: cardiotoxicity. Despite extensive research on the subject, our understanding of the tools for identifying and preventing these complications is limited.
To promote collaboration and efficiency, the MD Anderson Cancer Center developed an interdisciplinary team–based Heart Success Program to coordinate the management of concurrent cardiomyopathy and HF while the patient is receiving cancer treatment.
Medical monitoring and counseling can help us track and contain many harmful effects of cancer drug-induced cardiotoxicity. Patient engagement from the very beginning, along with medically advanced testing methods, can help us surmount cardiotoxicity and better ensure that patients receive only the benefits of essential cancer treatment.
With the explosion of new therapies in cancer care, the risk of each new therapy must be clearly understood prior to making treatment decisions with patients. Data from clinical trials alone are insufficient to educate these treatment choices, and real-world evidence from higher-risk populations should be generated to inform these treatment decisions.


Most Popular

AJMC Strategic Alliance